These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11426085)

  • 41. Abacavir hypersensitivity.
    Abel S; Paturel L; Cabié A
    N Engl J Med; 2008 Jun; 358(23):2515; author reply 2515-6. PubMed ID: 18536095
    [No Abstract]   [Full Text] [Related]  

  • 42. [New variations in highly active antiretroviral therapy. Simple combination as a promising option].
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():50-2. PubMed ID: 10863312
    [No Abstract]   [Full Text] [Related]  

  • 43. Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation.
    Gervasoni C; Vigano O; Grinelli E; Ortu M; Galli M; Rusconi S
    AIDS Patient Care STDS; 2007 Jan; 21(1):1-3. PubMed ID: 17263652
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Large lymphadenopathies complicating the abacavir hypersensitivity reaction.
    García JT; González PR; Hernández-Mora MG; Novoa SR; Quintana FB; Lahoz JG; Vázquez VS
    AIDS; 2007 Oct; 21(16):2254-6. PubMed ID: 18090059
    [No Abstract]   [Full Text] [Related]  

  • 45. Development of abacavir hypersensitivity reaction after rechallenge in a previously asymptomatic patient.
    El-Sahly HM
    AIDS; 2004 Jan; 18(2):359-60. PubMed ID: 15075569
    [No Abstract]   [Full Text] [Related]  

  • 46. Abacavir-induced agranulocytosis in two Taiwanese patients tested HLA-B*5701-negative.
    Chen SJ; Yang SP; Hung CC; Fung CP
    AIDS; 2010 May; 24(8):1238-9. PubMed ID: 20421748
    [No Abstract]   [Full Text] [Related]  

  • 47. Sweet's syndrome following abacavir therapy.
    Del Giudice P; Vandenbos F; Perrin C; Bernard E; Marq L; Dellamonica P
    J Am Acad Dermatol; 2004 Sep; 51(3):474-5. PubMed ID: 15337997
    [No Abstract]   [Full Text] [Related]  

  • 48. Abacavir hypersensitivity reaction.
    AIDS Patient Care STDS; 2002 May; 16(5):242. PubMed ID: 12058699
    [No Abstract]   [Full Text] [Related]  

  • 49. Understanding drug hypersensitivity: what to look for when prescribing abacavir.
    Hetherington S
    AIDS Read; 2001 Dec; 11(12):620-2. PubMed ID: 11806176
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Report from the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. HLA B-5701 and abacavir hypersensitivity.
    Albrecht H
    AIDS Clin Care; 2007 Oct; 19(10):81-2. PubMed ID: 18398994
    [No Abstract]   [Full Text] [Related]  

  • 51. Are disulfiram-like reactions associated with abacavir-containing antiretroviral regimens in clinical practice?
    Barber TJ; Marett B; Waldron S; Portsmouth S; Mackie NE; Weston R; Winston A
    AIDS; 2007 Aug; 21(13):1823-4. PubMed ID: 17690585
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Valuable combination partner. Great benefit for therapy naive patients].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():82-4. PubMed ID: 15373061
    [No Abstract]   [Full Text] [Related]  

  • 53. An unusual abacavir reaction.
    Fox J; Newton P; Daly R; Blume A; Marett B; Greene L; Winston A
    AIDS; 2008 Jul; 22(12):1520-2. PubMed ID: 18614878
    [No Abstract]   [Full Text] [Related]  

  • 54. Life-threatening reaction after first ever dose of abacavir in an HIV-1-infected patient.
    de la Rosa R; Harris M; Uyeda L; Goodison K; Keown P; Montaner JS
    AIDS; 2004 Feb; 18(3):578-9. PubMed ID: 15090818
    [No Abstract]   [Full Text] [Related]  

  • 55. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir.
    Phillips EJ; Sullivan JR; Knowles SR; Shear NH
    AIDS; 2002 Nov; 16(16):2223-5. PubMed ID: 12409746
    [No Abstract]   [Full Text] [Related]  

  • 56. How do abacavir and efavirenz differ in pharmacokinetics and toxicity?
    Edmunds-Ogbuokiri J
    Fac Notes (New Orleans La); 1999; 11(3):1-4. PubMed ID: 11810867
    [No Abstract]   [Full Text] [Related]  

  • 57. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.
    Hetherington S; McGuirk S; Powell G; Cutrell A; Naderer O; Spreen B; Lafon S; Pearce G; Steel H
    Clin Ther; 2001 Oct; 23(10):1603-14. PubMed ID: 11726000
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical and immunogenetic correlates of abacavir hypersensitivity.
    Phillips EJ; Wong GA; Kaul R; Shahabi K; Nolan DA; Knowles SR; Martin AM; Mallal SA; Shear NH
    AIDS; 2005 Jun; 19(9):979-81. PubMed ID: 15905681
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management protocol for abacavir-related hypersensitivity reaction.
    Clay PG; Rathbun RC; Slater LN
    Ann Pharmacother; 2000 Feb; 34(2):247-9. PubMed ID: 10676833
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-HIV agents. Who gets abacavir allergies?
    TreatmentUpdate; 2003 Oct; 15(6):4-5. PubMed ID: 17219615
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.